Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04378790

A Randomized Trial to Evaluate Sequential vs Simultaneous Patching

A Randomized Trial to Evaluate Sequential vs Simultaneous Spectacles Plus Patching for Amblyopia in Children 3 to <13 Years Old

Status
Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
544 (estimated)
Sponsor
Jaeb Center for Health Research · Academic / Other
Sex
All
Age
3 Years – 13 Years
Healthy volunteers
Not accepted

Summary

A randomized trial to determine whether simultaneous treatment with spectacles and patching has an equivalent VA outcome compared with sequential treatment, first with spectacles alone followed by patching (if needed), for previously untreated amblyopia in children 3 to \<13 years of age.

Detailed description

At an enrollment visit, distance VA will be measured in trial frames with or without cycloplegia based on a cycloplegic refraction performed within 30 days. If still apparently eligible, children will be prescribed spectacles and will then return for a spectacle baseline visit, where they will wear their new spectacles for the first time for at least 10 minutes (but no more than 24 hours) and will be tested in those new spectacles to confirm final eligibility prior to randomization. Participants not found to be eligible in their new spectacles will end study participation. Participants eligible for the study will be randomly allocated to one of two treatment groups: Sequential (spectacles alone) and then patching if needed (monitored by ODM), or Simultaneous (spectacles and patching monitored by ODM). After randomization, follow-up visits will occur at 8-week intervals through 56 weeks. At each visit on or after the 8-week visit, participants will be classified as either: stable/worsening or improving; those stable/worsening are then classified as having either resolved or residual amblyopia, provided that the current and most recent previous visit were completed at least 6-weeks apart (target 8 weeks) and provided the required test and retest VA testing was completed. Participants who are stable/worsening and have residual amblyopia in the sequential group will start patching (monitored by ODM) and continue to be followed every 8 weeks. Participants in the simultaneous group, or in the sequential group after having advanced to patching, who are stable/worsening but have residual amblyopia will be released to treatment at investigator discretion. All participants continue 8-weekly visits until 56 weeks when Study participation ends.

Conditions

Interventions

TypeNameDescription
OTHERPatchingProcedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.
OTHERGlassesEye Glasses are created and worn by patient to improve vision

Timeline

Start date
2020-12-08
Primary completion
2028-05-01
Completion
2028-05-01
First posted
2020-05-07
Last updated
2026-02-11

Locations

68 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04378790. Inclusion in this directory is not an endorsement.